Clinical trials
Completed Observational Peripheral Nervous System Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
48 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 48 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Celgene | 4 |
| Istanbul University | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 2 |
| Universitätsklinikum Hamburg-Eppendorf | 2 |
| Alnylam Pharmaceuticals | 1 |
| Assiut University | 1 |
| Beijing 3E-Regenacy Pharmaceuticals Co., Ltd. | 1 |
| Bioness Inc | 1 |
| CENTOGENE GmbH Rostock | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peripheral Nervous System Diseases | 48 |
| Arrhythmias, Cardiac | 6 |
| Heart Failure | 6 |
| Multiple Myeloma | 5 |
| Renal Insufficiency | 5 |
| Breast Neoplasms | 4 |
| Chronic Pain | 4 |
| Hypersensitivity | 4 |
| Infections | 4 |
| Lung Diseases, Interstitial | 4 |
Trials
Showing 1 to 25 of 48. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.